TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer

Immunology and Cell Biology

Volumn 84, Issue 1, 2006, Pages 87-98

  Cretney, Erika ^a   Shanker, Anil ^b   Yagita, Hideo ^c   Smyth, Mark J ^a   Sayers, Thomas J ^b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b NATIONAL CANCER INSTITUTE   (United States)

^c JUNTENDO UNIVERSITY   (Japan)

Author keywords

Apo2L; Autoimmune disease; Cancer; Encephalomyelitis; MD5 1; TNF related apoptosis inducing ligand

Indexed keywords

2 METHOXYESTRADIOL; ALPHA GALACTOSYLCERAMIDE; ALPHA INTERFERON; BETA INTERFERON; BORTEZOMIB; CAMPTOTHECIN; CISPLATIN; CYCLOHEXIMIDE; DACTINOMYCIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 12; IRINOTECAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DR4; MONOCLONAL ANTIBODY DR5; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROTEASOME INHIBITOR; RECOMBINANT PROTEIN; RESVERATROL; RETINOIC ACID; TRITERPENOID; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUNICAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHROMOSOME 8P; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DIABETES MELLITUS; DISEASE PREDISPOSITION; DISEASE SEVERITY; DNA MODIFICATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; EPITHELIUM CELL; GENE MUTATION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; INFLAMMATION; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; RNA INTERFERENCE; SENSITIZATION; SIGNAL TRANSDUCTION; THYMOCYTE; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; AUTOIMMUNE DISEASES; CLINICAL TRIALS; HUMANS; MEMBRANE GLYCOPROTEINS; MODELS, BIOLOGICAL; NEOPLASMS; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA;

EID: 33645091240     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1111/j.1440-1711.2005.01413.x     Document Type: Review

References (140)

1. Jin Z el Deiry WS Overview of cell death signaling pathways Cancer Biol. Ther 2005 4 139 63
2. Boatright KM Renatus M Scott FL et al A unified model for apical caspase activation Mol. Cell 2003 11 529 41
3. Lamhamedi-Cherradi SE Zheng SJ Maguschak KA Peschon J Chen YH Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice Nat. Immunol 2003 4 255 60
4. Corazza N Brumatti G Jakob S Villunger A Brunner T TRAIL and thymocyte apoptosis: not so deadly? Cell Death Differ 2004 11 Suppl. 2 S213 15
5. Simon AK Williams O Mongkolsapaya J et al Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: sensitivity of human thymocytes Proc. Natl Acad. Sci. USA 2001 98 5158 63
6. Smith KG Strasser A Vaux DL CrmA expression in T lymphocytes of transgenic mice inhibits CD95 (Fas/APO-1)-transduced apoptosis, but does not cause lymphadenopathy or autoimmune disease EMBO J 1996 15 5167 76
7. Newton K Harris AW Bath ML Smith KG Strasser A A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes EMBO J 1998 17 706 18
8. Green DR The suicide in the thymus, a twisted trail Nat. Immunol 2003 4 207 8
9. Rincon M Whitmarsh A Yang DD et al The JNK pathway regulates the in vivo deletion of immature CD4(+)CD8(+) thymocytes J. Exp. Med 1998 188 1817 30
10. Sabapathy K Hu Y Kallunki T et al JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development Curr. Biol 1999 9 116 25
11. Cretney E Uldrich AP Berzins SP Strasser A Godfrey DI Smyth MJ Normal thymocyte negative selection in TRAIL-deficient mice J. Exp. Med 2003 198 491 6
12. Diehl GE Yue HH Hsieh K et al TRAIL-R as a negative regulator of innate immune cell responses Immunity 2004 21 877 89
13. Tanaka Y Mamalaki C Stockinger B Kioussis D In vitro negative selection of alpha beta T cell receptor transgenic thymocytes by conditionally immortalized thymic cortical epithelial cell lines and dendritic cells Eur. J. Immunol 1993 23 2614 21
14. Hoffmann MW Heath WR Ruschmeyer D Miller JF Deletion of high-avidity T cells by thymic epithelium Proc. Natl Acad. Sci. USA 1995 92 9851 5
15. Sprent J Webb SR Intrathymic and extrathymic clonal deletion of T cells Curr. Opin. Immunol 1995 7 196 205
16. Song K Chen Y Goke R et al Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression J. Exp. Med 2000 191 1095 104
17. Lamhamedi-Cherradi SE Zheng S Tisch RM Chen YH Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes Diabetes 2003 52 2274 8
18. Mi QS Ly D Lamhamedi-Cherradi SE et al Blockade of tumor necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD mice Diabetes 2003 52 1967 75
19. Cretney E McQualter JL Kayagaki N et al TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice Immunol. Cell Biol 2005 83 511 19
20. Hilliard B Wilmen A Seidel C Liu TS Goke R Chen Y Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis J. Immunol 2001 166 1314 19
21. Aktas O Smorodchenko A Brocke S et al Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL Neuron 2005 46 421 32
22. Morel J Audo R Hahne M Combe B Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt J. Biol. Chem 2005 280 15 709 18
23. Wendling U Walczak H Dorr J et al Expression of TRAIL receptors in human autoreactive and foreign antigen-specific T cells Cell Death Differ 2000 7 637 44
24. Park YW Ji JD Lee JS Ryang DW Yoo DH Actinomycin D renders cultured synovial fibroblasts susceptible to tumour necrosis factor related apoptosis-inducing ligand (TRAIL)-induced apoptosis Scand. J. Rheumatol 2003 32 356 63
25. Miranda-Carus ME Balsa A Benito-Miguel M De Ayala CP Martin-Mola E Rheumatoid arthritis synovial fluid fibroblasts express TRAIL-R2 (DR5) that is functionally active Arthritis Rheum 2004 50 2786 93
26. Miyashita T Kawakami A Nakashima T et al Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells Clin. Exp. Immunol 2004 137 430 36
27. Wandinger KP Lunemann JD Wengert O et al TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis Lancet 2003 361 2036 43
28. Huang WX Huang MP Gomes MA Hillert J Apoptosis mediators fasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS Neurology 2000 55 928 34
29. Liu Z Xu X Hsu HC et al CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis J. Clin. Invest 2003 112 1332 41
30. Hirata S Senju S Matsuyoshi H Fukuma D Uemura Y Nishimura Y Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand J. Immunol 2005 174 1888 97
31. Ichikawa K Liu W Fleck M et al TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis J. Immunol 2003 171 1061 9
32. Yao Q Wang S Gambotto A et al Intra-articular adenoviral-mediated gene transfer of trail induces apoptosis of arthritic rabbit synovium Gene Ther 2003 10 1055 60
33. Pender MP Wolfe NP Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects Intern. Med. J 2002 32 554 63
34. Smyth MJ Hayakawa Y Takeda K Yagita H New aspects of natural-killer-cell surveillance and therapy of cancer Nat. Rev. Cancer 2002 2 850 61
35. Takeda K Hayakawa Y Smyth MJ et al Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells Nat. Med 2001 7 94 100
36. Takeda K Smyth MJ Cretney E et al Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development J. Exp. Med 2002 195 161 9
37. Cretney E Takeda K Yagita H Glaccum M Peschon JJ Smyth MJ Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice J. Immunol 2002 168 1356 61
38. Seki N Hayakawa Y Brooks AD et al Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer Cancer Res 2003 63 207 13
39. Smyth MJ Cretney E Takeda K et al Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis J. Exp. Med 2001 193 661 70
40. Hayakawa Y Takeda K Yagita H et al Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide Eur. J. Immunol 2001 31 1720 27
41. Zerafa N Westwood JA Cretney E et al Cutting edge: TRAIL deficiency accelerates hematological malignancies J. Immunol 2005 175 5586 90
42. LeBlanc H Lawrence D Varfolomeev E et al Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax Nat. Med 2002 8 274 81
43. Lee SH Shin MS Kim HS et al Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers Cancer Res 1999 59 5683 6
44. Lee SH Shin MS Kim HS et al Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma Oncogene 2001 20 399 403
45. Shin MS Kim HS Lee SH et al Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers Cancer Res 2001 61 4942 6
46. Fisher MJ Virmani AK Wu L et al Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer Clin. Cancer Res 2001 7 1688 97
47. Horak P Pils D Haller G et al Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer Mol. Cancer Res 2005 3 335 43
48. Hazra A Chamberlain RM Grossman HB Zhu Y Spitz MR Wu X Death receptor 4 and bladder cancer risk Cancer Res 2003 63 1157 9
49. Frank B Hemminki K Shanmugam KS et al Association of death receptor 4 haplotype 626C-683C with an increased risk of breast cancer Carcinogenesis 2005 26 1975 7
50. Fulda S Meyer E Friesen C Susin SA Kroemer G Debatin KM Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis Oncogene 2001 20 1063 75
51. Philchenkov A Zavelevich M Kroczak TJ Los M Caspases and cancer: mechanisms of inactivation and new treatment modalities Exp. Oncol 2004 26 82 97
52. Griffith TS Chin WA Jackson GC Lynch DH Kubin MZ Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells J. Immunol 1998 161 2833 40
53. Kim K Fisher MJ Xu SQ el Deiry WS Molecular determinants of response to TRAIL in killing of normal and cancer cells Clin. Cancer Res 2000 6 335 46
54. Dolcet X Llobet D Pallares J Rue M Comella JX Matias-Guiu X FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis Lab Invest 2005 85 885 94
55. Zhang XD Franco A Myers K Gray C Nguyen T Hersey P Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma Cancer Res 1999 59 2747 53
56. Siegmund D Hadwiger P Pfizenmaier K Vornlocher HP Wajant H Selective inhibition of FLICE-like inhibitory protein (FLIP) expression with small interfering RNA oligonucleotides (siRNAs) is sufficient to sensitize tumor cells for TRAIL-induced apoptosis Mol. Med 2002 8 725 32
57. Brooks AD Sayers TJ Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis Cancer Immunol. Immunother 2005 54 499 505
58. Sharp DA Lawrence DA Ashkenazi A Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis J. Biol. Chem 2005 280 19 401 9
59. Burns TF el Deiry WS Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach J. Biol. Chem 2001 276 37 879 86
60. Kayagaki N Yamaguchi N Nakayama M Eto H Okumura K Yagita H Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs J. Exp. Med 1999 189 1451 60
61. Griffith TS Wiley SR Kubin MZ Sedger LM Maliszewski CR Fanger NA Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL J. Exp. Med 1999 189 1343 54
62. Fanger NA Maliszewski CR Schooley K Griffith TS Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) J. Exp. Med 1999 190 1155 64
63. Koga Y Matsuzaki A Suminoe A Hattori H Hara T Neutrophil-derived TNF-related apoptosis-inducing ligand (TRAIL): a novel mechanism of antitumor effect by neutrophils Cancer Res 2004 64 1037 43
64. Ludwig AT Moore JM Luo Y et al Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin- induced antitumor activity Cancer Res 2004 64 3386 90
65. Altucci L Rossin A Raffelsberger W Reitmair A Chomienne C Gronemeyer H Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL Nat. Med 2001 7 680 86
66. Nebbioso A Clarke N Voltz E et al Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells Nat. Med 2005 11 77 84
67. Schmaltz C Alpdogan O Kappel BJ et al T cells require TRAIL for optimal graft-versus-tumor activity Nat. Med 2002 8 1433 7
68. Daniels RA Turley H Kimberley FC et al Expression of TRAIL and TRAIL receptors in normal and malignant tissues Cell Res 2005 15 430 38
69. Almasan A Ashkenazi A Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy Cytokine Growth Factor Rev 2003 14 337 48
70. Yagita H Takeda K Hayakawa Y Smyth MJ Okumura K TRAIL and its receptors as targets for cancer therapy Cancer Sci 2004 95 777 83
71. Walczak H Miller RE Ariail K et al Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo Nat. Med 1999 5 157 63
72. Mitsiades CS Treon SP Mitsiades N et al TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications Blood 2001 98 795 804
73. Naka T Sugamura K Hylander BL Widmer MB Rustum YM Repasky EA Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice Cancer Res 2002 62 5800 806
74. Hylander BL Pitoniak R Penetrante RB et al The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice J. Transl. Med 2005 3 22
75. Kelley SK Harris LA Xie D et al Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety J. Pharmacol. Exp. Ther 2001 299 31 8
76. Ichikawa K Liu W Zhao L et al Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity Nat. Med 2001 7 954 60
77. Griffith TS Rauch CT Smolak PJ et al Functional analysis of TRAIL receptors using monoclonal antibodies J. Immunol 1999 162 2597 605
78. Chuntharapai A Dodge K Grimmer K et al Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4 J. Immunol 2001 166 4891 8
79. Humphreys RC Development and evaluation of cancer therapeutic agents targeting TRAIL receptor 1 and 2 In La Rochelle WJ Shimkets RA eds Cancer Drug Discovery and Development: The Oncogenomics Handbook Humana Press Totowa, NJ 2005 659 76
80. Georgakis GV Li Y Humphreys R et al Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death Br. J. Haematol 2005 130 501 10
81. Pukac L Kanakaraj P Humphreys R et al HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo Br. J. Cancer 2005 92 1430 41
82. Motoki K Mori E Matsumoto A et al Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 Clin. Cancer Res 2005 11 3126 35
83. Halpern W Lincoln C Roach C et al TRAIL-R2 expression in normal and tumor tissues Ann. Oncol 2004 15 Suppl. 3 iii22
84. Halpern W Lincoln C Sharifi A Askaa J Klein-Szanto A Cohen R Variable distribution of TRAIL receptor 1 in primary human tumor and normal tissues Eur. J. Cancer 2004 2 Suppl. 8 69
85. Takeda K Yamaguchi N Akiba H et al Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy J. Exp. Med 2004 199 437 48
86. Chinnaiyan AM Prasad U Shankar S et al Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy Proc. Natl Acad. Sci. USA 2000 97 1754 9
87. Gong B Almasan A Apo2 ligand/TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells Cancer Res 2000 60 5754 60
88. Ciusani E Croci D Gelati M et al In vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant glioma J. Neurooncol 2005 71 19 25
89. Marini P Schmid A Jendrossek V et al Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis BMC Cancer 2005 5 5
90. Ramp U Caliskan E Mahotka C et al Apoptosis induction in renal cell carcinoma by TRAIL and gamma-radiation is impaired by deficient caspase-9 cleavage Br. J. Cancer 2003 88 1800 807
91. Shanker S Singh TR Shrivastava RK Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: intracellular mechanisms Prostate 2004 61 35 49
92. Finnberg N Gruber JJ Fei P et al DR5 knockout mice are compromised in radiation-induced apoptosis Mol. Cell Biol 2005 25 2000 2013
93. LeBlanc HN Ashkenazi A Apo2L/TRAIL and its death and decoy receptors Cell Death Differ 2003 10 66 75
94. Van Geelen CMM de Vries EGE de Jong S Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy Drug Resist. Updat 2005 7 345 58
95. Wang S el Deiry WS Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy Proc. Natl Acad. Sci. USA 2003 100 15 095 100
96. Debatin KM Krammer PH Death receptors in chemotherapy and cancer Oncogene 2004 23 2950 66
97. Ravi R Jain AJ Schulick RD et al Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL Cancer Res 2004 64 9105 14
98. Adams J Proteasome inhibition in cancer: development of PS-341 Semin. Oncol 2001 28 613 19
99. Adams J Palombella VJ Sausville EA et al Proteasome inhibitors: a novel class of potent and effective antitumor agents Cancer Res 1999 59 2615 22
100. Elliott PJ Ross JS The proteasome: a new target for novel drug therapies Am. J. Clin. Pathol 2001 116 637 46
101. Landowski TH Megli CJ Nullmeyer KD Lynch RM Dorr RT Mitochondrial- mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines Cancer Res 2005 65 3828 36
102. Fernandez Y Verhaegen M Miller TP et al Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications Cancer Res 2005 65 6294 304
103. Qin JZ Ziffra J Stennett L et al Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells Cancer Res 2005 65 6282 93
104. Matta H Chaudhary PM The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells Cancer Biol. Ther 2005 4 77 82
105. An J Sun YP Adams J Fisher M Belldegrun A Rettig MB Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer Clin. Cancer Res 2003 9 4537 45
106. Kim Y Suh N Sporn M Reed JC An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis J. Biol. Chem 2002 277 22 320 29
107. Sayers TJ Brooks AD Koh CY et al The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP Blood 2003 102 303 10
108. He Q Huang Y Sheikh MS Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells Oncogene 2004 23 2554 8
109. Leverkus M Sprick MR Wachter T et al Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation Mol. Cell Biol 2003 23 777 90
110. Nikrad M Johnson T Puthalalath H Coultas L Adams J Kraft AS The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther 2005 4 443 9
111. Lashinger LM Zhu K Williams SA Shrader M Dinney CP McConkey DJ Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells Cancer Res 2005 65 4902 8
112. Puduvalli VK Sampath D Bruner JM Nangia J Xu R Kyritsis AP TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation Apoptosis 2005 10 233 43
113. Johnson TR Stone K Nikrad M et al The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells Oncogene 2003 22 4953 63
114. Ganten TM Koschny R Haas TL et al Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL Hepatology 2005 42 588 97
115. McDonald ER III. el Deiry WS Suppression of caspase-8- and -10-associated RING proteins results in sensitization to death ligands and inhibition of tumor cell growth Proc. Natl Acad. Sci. USA 2004 101 6170 75
116. Suzuki Y Nakabayashi Y Takahashi R Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death Proc. Natl Acad. Sci. USA 2001 98 8662 7
117. Zhang XM Lin H Chen C Chen BD Inhibition of ubiquitin-proteasome pathway activates a caspase-3-like protease and induces Bcl-2 cleavage in human M-07e leukaemic cells Biochem. J 1999 340 127 33
118. Chen L Smith L Wang Z Smith JB Preservation of caspase-3 subunits from degradation contributes to apoptosis evoked by lactacystin: any single lysine or lysine pair of the small subunit is sufficient for ubiquitination Mol. Pharmacol 2003 64 334 45
119. Luo JL Maeda S Hsu LC Yagita H Karin M Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression Cancer Cell 2004 6 297 305
120. Merchant MS Yang X Melchionda F et al Interferon gamma enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma Cancer Res 2004 64 8349 56
121. Papageorgiou A Lashinger L Millikan R et al Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells Cancer Res 2004 64 8973 9
122. Fulda S Debatin KM Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol Oncogene 2004 23 6702 11
123. Shiraishi T Yoshida T Nakata S et al Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells Cancer Res 2005 65 6364 70
124. Jin Z McDonald ER III. Dicker DT el Deiry WS Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis J. Biol. Chem 2004 279 35 829 39
125. Vanoosten RL Moore JM Karacay B Griffith TS Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression Cancer Biol. Ther 2005 4 1104 12
126. Guo F Sigua C Tao J et al Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells Cancer Res 2004 64 2580 89
127. LaVallee TM Zhan XH Johnson MS et al 2-Methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway Cancer Res 2003 63 468 75
128. Hyer ML Croxton R Krajewska M et al Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells Cancer Res 2005 65 4799 808
129. Lu M Kwan T Yu C et al Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest J. Biol. Chem 2005 280 6742 51
130. Fulda S Debatin KM Signaling through death receptors in cancer therapy Curr. Opin. Pharmacol 2004 4 327 32
131. Izeradjene K Douglas L Tillman DM Delaney AB Houghton JA Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines Cancer Res 2005 65 7436 45
132. Wirth T Kuhnel F Fleischmann-Mundt B et al Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1 Cancer Res 2005 65 7393 402
133. Wajant H Gerspach J Pfizenmaier K Tumor therapeutics by design: targeting and activation of death receptors Cytokine Growth Factor Rev 2005 16 55 76
134. Walensky LD Kung AL Escher I et al Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix Science 2004 305 1466 70
135. Oltersdorf T Elmore SW Shoemaker AR et al An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 2005 435 677 81
136. Fulda S Wick W Weller M Debatin KM Smac agonists sensitize for Apo2L/T- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo Nat. Med 2002 8 808 15
137. Li L Thomas RM Suzuki H De Brabander JK Wang X Harran PG A small molecule Smac mimic potentiates TRAIL- and TNFα-mediated cell death Science 2004 305 1471 4
138. Janssen EM Droin NM Lemmens EE et al CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death Nature 2005 434 88 93
139. Ehrhardt H Fulda S Schmid I Hiscott J Debatin KM Jeremias I TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB Oncogene 2003 22 3842 52
140. Mills KR Reginato M Debnath J Queenan B Brugge JS Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is required for induction of autophagy during lumen formation in vitro Proc. Natl Acad. Sci USA 2004 101 3438 43